文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

N-乙酰-L-半胱氨酸、地西他滨联合改良BUCY方案用于髓系恶性肿瘤患者异基因造血干细胞移植前预处理

Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation.
PubMed 文献 · Am J Hematol · 2023-03-23

一项前瞻性随机对照试验评估改良BUCY联合地西他滨和N-乙酰-L-半胱氨酸预处理对髓系恶性肿瘤异基因造血干细胞移植受者结局的影响。A组76例、B组78例纳入最终分析,A组血小板恢复更快、复发累积发生率更低、3年无事件生存率更高,3年总生存率两组无显著差异。

要点

  • A组+30天和+60天血小板计数≥50×10^9/L的患者多于B组(p=.004和.043)。
  • A组复发累积发生率为11.8%(95%CI 0.06-0.22),低于B组的24.4%(95%CI 0.16-0.35)(p=.048)。
  • 3年无事件生存率A组为79.2%(±4.9%),高于B组的60.0%(±5.9%)(p=.007)。

核心结论

  • 在改良BUCY方案基础上加用地西他滨和N-乙酰-L-半胱氨酸,对髓系恶性肿瘤患者是一种可行且有前景的预处理方案。

研究设计与样本

  • 前瞻性随机对照试验,纳入接受异基因造血干细胞移植的髓系恶性肿瘤患者,随机分为A组(地西他滨第-12至-10天;N-乙酰-L-半胱氨酸第-9至+30天;改良BUCY第-9至-2天)和B组(改良BUCY方案后输注干细胞)。
  • 最终评估A组76例、B组78例。

主要发现

  • A组血小板恢复加快,+30天和+60天达到血小板计数≥50×10^9/L的患者多于B组(p=.004和.043)。
  • 复发累积发生率A组为11.8%(95%CI 0.06-0.22),B组为24.4%(95%CI 0.16-0.35)(p=.048)。
  • 估计3年总生存率A组为86.4%(±4.4%),B组为79.9%(±4.7%)(p=.155)。
  • 3年无事件生存率A组为79.2%(±4.9%),B组为60.0%(±5.9%)(p=.007)。
  • 细胞内活性氧水平与血小板恢复呈负相关,A组造血祖细胞内活性氧过高的患者少于B组。

临床怎么用

  • 作者认为,在改良BUCY方案基础上加用地西他滨和N-乙酰-L-半胱氨酸是髓系恶性肿瘤患者可行且有前景的预处理方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Conditioning therapy is an essential procedure prior to hematopoietic stem cell transplant (HSCT), imposing a great impact on the outcomes of recipients. We performed a prospective randomized controlled trial to assess the outcome of HSCT recipients with myeloid malignancies after receiving the conditioning therapy consisting of modified BUCY (mBUCY), N-acetyl-L-cysteine (NAC), and decitabine. Enrolled patients were randomly allocated to either Arm A (decitabine, day -12 to -10; NAC, day -9 to +30; mBUCY, day -9 to -2), or Arm B (mBUCY regimen followed by stem cells infusion). Seventy-six patients in Arm A and 78 patients in Arm B were finally evaluated. The results showed platelet recovery accelerate in Arm A, with more patients achieving a platelet count of ≥50 × 109 /L than Arm B at day +30 and +60 (p = .004 and .043, respectively). The cumulative incidence of relapse is 11.8% (95% CI 0.06-0.22) in Arm A, and 24.4% (95% CI 0.16-0.35) in Arm B (p = .048). The estimated 3-year overall survival rate was 86.4% (±4.4%) and 79.9% (±4.7%) in 2 arms, respectively (p = .155). EFS at 3 years was 79.2% (±4.9%) in Arm A and 60.0% (±5.9%) in Arm B (p = .007). Intracellular reactive oxygen species (ROS) level was found to be reversely correlated with platelet recovery, and fewer patients in Arm A displayed excessive ROS within hematopoietic progenitor cells compared to Arm B. In conclusion, the addition of decitabine and NAC to mBUCY is a feasible and promising conditioning therapy for myeloid malignancies patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Tang Y, Zhang Z, Liu S, et al. Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2023. PMID: 36880836. doi:10.1002/ajh.26903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。